

Applicant : Kreutzer *et al.*
Serial No. : 10/612,179
Filed : July 2, 2003
Page : 5 of 10

Attorney's Docket No.:
14174-104US5 / R18001.3USD4

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-3. (Cancelled)

4. (Currently amended) An isolated oligoribonucleotide consisting of two separate non-linked complementary oligoribonucleotide strands (dsRNA),

wherein the dsRNA is ~~not more than~~ 15 to 21 nucleotides in length,

wherein the dsRNA does not comprise a full length RNA transcript of a mammalian target gene,

wherein one strand of the dsRNA is complementary to less than the full length of an RNA transcript of said mammalian target gene,

and wherein the oligoribonucleotide specifically inhibits the expression of said mammalian target gene.

5. (Currently amended) The oligoribonucleotide of claim 4, wherein said dsRNA consists of a length of ~~between 15 and 21~~ nucleotides.

6. (Previously presented) The oligoribonucleotide of claim 4, wherein the RNA transcript is a primary or a processed RNA.

7. (Previously presented) The oligoribonucleotide of claim 4, wherein said oligoribonucleotide is modified so as to be resistant to RNA degradation.

Applicant : Kreutzer *et al.*

Serial No. : 10/612,179

Filed : July 2, 2003

Page : 6 of 10

Attorney's Docket No.:
14174-104USS / RJB001.3USD4

8. (Previously presented) The oligoribonucleotide of claim 4, wherein said one strand of said dsRNA is fully complementary to less than the full length of an RNA transcript of a mammalian target gene.

9. (Previously presented) The oligoribonucleotide of claim 4 or 8, wherein said two separate complementary strands are fully complementary to each other.

10-15. (Cancelled)